Analyses of tumor-infiltrating immune cells indicated that tumor-bearing mice receiving coadministration of a-Egfl6 and a-PD-L1 Abs displayed (a) a significant reduction of CD206+ TAMs (Figure 5D) and PMN-MDSCs (Figure 5E) and (b) an increased number of MHCII+ TAMs (Figure 5F) compared with mice receiving single treatment of a-Egfl6 Ab, a-PD-L1 Ab, or IgG isotype Ab control. The gene discussed is MRC1; the disease is neoplasm.